vs
AMREP CORP.（AXR）与Cytosorbents Corp（CTSO）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是Cytosorbents Corp的1.6倍（$14.6M vs $9.2M），AMREP CORP.净利率更高（21.6% vs -59.5%，领先81.1%），AMREP CORP.同比增速更快（93.8% vs 0.9%），AMREP CORP.自由现金流更多（$5.4M vs $-4.9M），过去两年Cytosorbents Corp的营收复合增速更高（1.3% vs -13.6%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
Cytosorbents是一家公开上市企业，总部位于美国新泽西州普林斯顿，专注于血液净化领域相关医疗产品的研发与商业化，核心产品应用于重症救治场景，帮助去除患者血液中的炎性介质等有害物质。
AXR vs CTSO — 直观对比
营收规模更大
AXR
是对方的1.6倍
$9.2M
营收增速更快
AXR
高出92.9%
0.9%
净利率更高
AXR
高出81.1%
-59.5%
自由现金流更多
AXR
多$10.3M
$-4.9M
两年增速更快
CTSO
近两年复合增速
-13.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $9.2M |
| 净利润 | $3.1M | $-5.5M |
| 毛利率 | — | 73.7% |
| 营业利润率 | 20.6% | -47.5% |
| 净利率 | 21.6% | -59.5% |
| 营收同比 | 93.8% | 0.9% |
| 净利润同比 | 338.9% | 27.4% |
| 每股收益（稀释后） | $0.58 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRCTSO
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $9.2M | ||
| Q3 25 | $17.9M | $9.5M | ||
| Q2 25 | $11.2M | $9.6M | ||
| Q1 25 | $7.5M | $8.7M | ||
| Q4 24 | $11.9M | $9.2M | ||
| Q3 24 | $19.1M | $8.6M | ||
| Q2 24 | $19.5M | $8.8M |
净利润AXRCTSO
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-5.5M | ||
| Q3 25 | $4.7M | $-3.2M | ||
| Q2 25 | $3.9M | $1.9M | ||
| Q1 25 | $717.0K | $-1.5M | ||
| Q4 24 | $4.0M | $-7.6M | ||
| Q3 24 | $4.1M | $-2.8M | ||
| Q2 24 | $4.1M | $-4.3M |
毛利率AXRCTSO
| Q1 26 | — | — | ||
| Q4 25 | — | 73.7% | ||
| Q3 25 | — | 70.3% | ||
| Q2 25 | — | 70.9% | ||
| Q1 25 | — | 71.1% | ||
| Q4 24 | — | 68.4% | ||
| Q3 24 | — | 61.0% | ||
| Q2 24 | — | 73.5% |
营业利润率AXRCTSO
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -47.5% | ||
| Q3 25 | 34.4% | -30.2% | ||
| Q2 25 | 31.7% | -37.6% | ||
| Q1 25 | 5.7% | -44.5% | ||
| Q4 24 | 26.4% | -37.1% | ||
| Q3 24 | 26.1% | -56.1% | ||
| Q2 24 | 23.9% | -40.4% |
净利率AXRCTSO
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -59.5% | ||
| Q3 25 | 26.3% | -33.4% | ||
| Q2 25 | 34.8% | 20.2% | ||
| Q1 25 | 9.5% | -16.9% | ||
| Q4 24 | 33.9% | -82.7% | ||
| Q3 24 | 21.3% | -32.1% | ||
| Q2 24 | 21.2% | -48.6% |
每股收益（稀释后）AXRCTSO
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $-0.09 | ||
| Q3 25 | $0.87 | $-0.05 | ||
| Q2 25 | $0.73 | $0.03 | ||
| Q1 25 | $0.13 | $-0.02 | ||
| Q4 24 | $0.75 | $-0.14 | ||
| Q3 24 | $0.76 | $-0.05 | ||
| Q2 24 | $0.77 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $6.2M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $5.9M |
| 总资产 | $143.9M | $44.2M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRCTSO
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $6.2M | ||
| Q3 25 | $48.9M | $7.5M | ||
| Q2 25 | $39.5M | $10.2M | ||
| Q1 25 | $36.9M | $11.6M | ||
| Q4 24 | $40.1M | $3.3M | ||
| Q3 24 | $40.4M | $5.7M | ||
| Q2 24 | $29.7M | $8.5M |
总债务AXRCTSO
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | $13.8M | ||
| Q2 24 | $35.0K | $13.7M |
股东权益AXRCTSO
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $5.9M | ||
| Q3 25 | $134.7M | $9.0M | ||
| Q2 25 | $130.0M | $11.6M | ||
| Q1 25 | $126.0M | $14.5M | ||
| Q4 24 | $125.1M | $11.1M | ||
| Q3 24 | $122.2M | $13.4M | ||
| Q2 24 | $118.0M | $17.4M |
总资产AXRCTSO
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $44.2M | ||
| Q3 25 | $140.7M | $45.8M | ||
| Q2 25 | $133.8M | $48.0M | ||
| Q1 25 | $128.9M | $50.8M | ||
| Q4 24 | $129.1M | $47.4M | ||
| Q3 24 | $127.0M | $47.8M | ||
| Q2 24 | $122.8M | $53.4M |
负债/权益比AXRCTSO
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | 1.03× | ||
| Q2 24 | 0.00× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $-4.8M |
| 自由现金流经营现金流 - 资本支出 | $5.4M | $-4.9M |
| 自由现金流率自由现金流/营收 | 37.0% | -53.4% |
| 资本支出强度资本支出/营收 | 0.1% | 1.2% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | $-12.5M |
8季度趋势，按日历期对齐
经营现金流AXRCTSO
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-4.8M | ||
| Q3 25 | $9.5M | $-2.6M | ||
| Q2 25 | $10.2M | $-1.5M | ||
| Q1 25 | $-3.2M | $-3.5M | ||
| Q4 24 | $-182.0K | $-2.3M | ||
| Q3 24 | $10.7M | $-2.5M | ||
| Q2 24 | $10.7M | $-4.8M |
自由现金流AXRCTSO
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-4.9M | ||
| Q3 25 | $9.5M | $-2.6M | ||
| Q2 25 | $9.7M | $-1.5M | ||
| Q1 25 | $-3.3M | $-3.5M | ||
| Q4 24 | $-268.0K | $-2.4M | ||
| Q3 24 | $10.7M | $-2.6M | ||
| Q2 24 | $10.3M | $-4.8M |
自由现金流率AXRCTSO
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | -53.4% | ||
| Q3 25 | 53.2% | -27.3% | ||
| Q2 25 | 86.4% | -16.1% | ||
| Q1 25 | -43.4% | -39.7% | ||
| Q4 24 | -2.3% | -26.3% | ||
| Q3 24 | 55.8% | -30.4% | ||
| Q2 24 | 52.5% | -54.4% |
资本支出强度AXRCTSO
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 1.2% | ||
| Q3 25 | 0.1% | 0.2% | ||
| Q2 25 | 5.2% | 0.4% | ||
| Q1 25 | 0.3% | 0.0% | ||
| Q4 24 | 0.7% | 0.8% | ||
| Q3 24 | 0.2% | 1.8% | ||
| Q2 24 | 2.3% | 0.2% |
现金转化率AXRCTSO
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | -0.78× | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXR
暂无分部数据
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
